Cargando…

The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was originally discovered in prokaryotes and functions as part of the adaptive immune system. The experimental research of many scholars, as well as scientific and technological advanceme...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Wei, Li, Tao, Wang, Shanshan, Wang, Huihui, Li, Xuemei, Zhang, Shubing, Wang, Lianzi, Xu, Yuanhong, Wei, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493308/
https://www.ncbi.nlm.nih.gov/pubmed/34605326
http://dx.doi.org/10.1177/15330338211045206
_version_ 1784579096171249664
author Lv, Wei
Li, Tao
Wang, Shanshan
Wang, Huihui
Li, Xuemei
Zhang, Shubing
Wang, Lianzi
Xu, Yuanhong
Wei, Wei
author_facet Lv, Wei
Li, Tao
Wang, Shanshan
Wang, Huihui
Li, Xuemei
Zhang, Shubing
Wang, Lianzi
Xu, Yuanhong
Wei, Wei
author_sort Lv, Wei
collection PubMed
description The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was originally discovered in prokaryotes and functions as part of the adaptive immune system. The experimental research of many scholars, as well as scientific and technological advancements, has allowed prokaryote-derived CRISPR/Cas genome-editing systems to transform our ability to manipulate, detect, image, and annotate specific DNA and RNA sequences in the living cells of diverse species. Through modern genetic engineering editing technology and high-throughput gene sequencing, we can edit and splice covalently closed circular DNA to silence it, and correct the mutation and deletion of liver cancer genes to achieve precise in situ repair of defective genes and prohibit viral infection or replication. Such manipulations do not destroy the structure of the entire genome and facilitate the cure of diseases. In this review, we discussed the possibility that CRISPR/Cas could be used as a treatment for patients with liver cancer caused by hepatitis B virus infection, and reviewed the challenges incurred by this effective gene-editing technology.
format Online
Article
Text
id pubmed-8493308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84933082021-10-07 The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer Lv, Wei Li, Tao Wang, Shanshan Wang, Huihui Li, Xuemei Zhang, Shubing Wang, Lianzi Xu, Yuanhong Wei, Wei Technol Cancer Res Treat Review The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was originally discovered in prokaryotes and functions as part of the adaptive immune system. The experimental research of many scholars, as well as scientific and technological advancements, has allowed prokaryote-derived CRISPR/Cas genome-editing systems to transform our ability to manipulate, detect, image, and annotate specific DNA and RNA sequences in the living cells of diverse species. Through modern genetic engineering editing technology and high-throughput gene sequencing, we can edit and splice covalently closed circular DNA to silence it, and correct the mutation and deletion of liver cancer genes to achieve precise in situ repair of defective genes and prohibit viral infection or replication. Such manipulations do not destroy the structure of the entire genome and facilitate the cure of diseases. In this review, we discussed the possibility that CRISPR/Cas could be used as a treatment for patients with liver cancer caused by hepatitis B virus infection, and reviewed the challenges incurred by this effective gene-editing technology. SAGE Publications 2021-10-04 /pmc/articles/PMC8493308/ /pubmed/34605326 http://dx.doi.org/10.1177/15330338211045206 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Lv, Wei
Li, Tao
Wang, Shanshan
Wang, Huihui
Li, Xuemei
Zhang, Shubing
Wang, Lianzi
Xu, Yuanhong
Wei, Wei
The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
title The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
title_full The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
title_fullStr The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
title_full_unstemmed The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
title_short The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
title_sort application of the crispr/cas9 system in the treatment of hepatitis b liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493308/
https://www.ncbi.nlm.nih.gov/pubmed/34605326
http://dx.doi.org/10.1177/15330338211045206
work_keys_str_mv AT lvwei theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT litao theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT wangshanshan theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT wanghuihui theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT lixuemei theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT zhangshubing theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT wanglianzi theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT xuyuanhong theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT weiwei theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT lvwei applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT litao applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT wangshanshan applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT wanghuihui applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT lixuemei applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT zhangshubing applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT wanglianzi applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT xuyuanhong applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer
AT weiwei applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer